Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

N., Kim; Chowdhury, Simon; Bjartell, Anders; Ha Chung, Byung; Juliana Gomes, Andrea; Given, Robert; Juárez, Álvaro; S. Merseburger, Axel; Özgüroğlu, Mustafa; Uemura, Hirotsugu; Ye, Dingwei; Brookman‐May, Sabine; Mundle, Suneel; McCarthy, Sharon; S. Larsen, Julie; Sun, Weili; B. Bevans, Katherine; Zhang, Ke; Bandyopadhyay, Nibedita; Agarwal, Neeraj

doi:10.1200/jco.20.03488

Public

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

Published in Journal of Clinical Oncology • Apr 29, 2021

Authors:

Kim N.

Simon Chowdhury

Anders Bjartell

Abstract

PURPOSE The first interim analysis of the phase III, randomized, placebo-controlled TITAN study showed that apalutamide significantly improved overall survival (OS) and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer (mCSPC) receiving ongoing a...

Subject

Medicine

Placebo

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!